Clinical trial
A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects
NCT02660736 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 29, 2016
- Completion date
- August 31, 2016
- Enrollment
- 59 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.